Toho Holdings Co., Ltd.
FY2026 Q3 Financial Summary [Japanese GAAP] (Consolidated)
For FY2026 Q3, net sales reached 1,183,158 million yen (1.8% YoY increase), operating income was 12,422 million yen (13.3% YoY decrease), and net income attributable to owners of parent for the quarter was 14,448 million yen (40.9% YoY increase).
Key Figures
- Net Sales: 1,183,158 million yen (1.8% YoY increase)
- Operating Income: 12,422 million yen (13.3% YoY decrease)
- Net Income Attributable to Owners of Parent: 14,448 million yen (40.9% YoY increase)
AI要約
Performance Overview
The consolidated results for FY2026 Q3 recorded net sales of 1,183,158 million yen (1.8% YoY increase), operating income of 12,422 million yen (13.3% YoY decrease), ordinary income of 14,168 million yen (11.7% YoY decrease), and net income attributable to owners of parent of 14,448 million yen (40.9% YoY increase). In the pharmaceutical wholesaling business, despite decreased demand for COVID-related products, net sales increased YoY due to expanded handling of specialty pharmaceuticals and enhanced customer support services. The dispensing pharmacy business achieved net sales of 75,394 million yen (4.4% YoY increase) and segment profit of 1,179 million yen (60.6% YoY increase), representing significant profit growth. The pharmaceutical manufacturing and sales business posted net sales of 8,750 million yen (1.0% YoY increase) and segment profit of 167 million yen (69.2% YoY decrease).
Financial Position and Dividend Status
Total assets stood at 826,097 million yen, up 14.3% from the previous consolidated fiscal year-end, and net assets increased by 4.7% to 268,939 million yen; however, the equity ratio declined from 35.5% to 32.5%. The annual dividend is planned at 120 yen (interim 45 yen, year-end 75 yen), a significant increase from 65 yen the previous year. Share buyback activities have also been conducted to improve capital efficiency and enhance shareholder returns.
